Elixiron Immunotherapeutics (Cayman) Limited (TPEX:7871)
Taiwan · Delayed Price · Currency is TWD 145.50
+6.50 (4.68%)
At close: Sep 7, 2026
TPEX:7871 Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Cash & Equivalents | 808.06 | 863.36 | 88.12 | 30.53 |
Cash & Short-Term Investments | 808.06 | 863.36 | 88.12 | 30.53 |
Cash Growth | 18.50% | 879.74% | 188.60% | - |
Accounts Receivable | - | 0.1 | 2.4 | 1.43 |
Other Receivables | 2 | 14.18 | 7.53 | 0.26 |
Receivables | 2 | 14.28 | 9.92 | 1.69 |
Prepaid Expenses | 9.2 | 6.15 | 1.25 | 0.79 |
Other Current Assets | - | - | 0.2 | 0.01 |
Total Current Assets | 819.26 | 883.79 | 99.49 | 33.03 |
Property, Plant & Equipment | 16.58 | 19.95 | 26.69 | 22.78 |
Long-Term Investments | - | - | - | 0.29 |
Other Intangible Assets | 14.64 | 15.61 | 12.59 | 14.4 |
Other Long-Term Assets | 11.69 | 10.83 | 9.86 | 10.01 |
Total Assets | 862.17 | 930.17 | 148.63 | 80.51 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Accrued Expenses | 32.35 | 54.82 | 27.71 | 51.13 |
Short-Term Debt | - | - | 1,345 | 731.92 |
Current Portion of Long-Term Debt | 6.5 | 6.5 | 6.5 | 6.5 |
Current Portion of Leases | 4.55 | 4.36 | 4.16 | 4.91 |
Current Income Taxes Payable | 38.22 | 18.86 | 3.93 | 3.68 |
Other Current Liabilities | 4.94 | 3.57 | 4.07 | 13.86 |
Total Current Liabilities | 86.56 | 88.11 | 1,392 | 812 |
Long-Term Debt | 2.17 | 5.42 | 11.92 | 18.42 |
Long-Term Leases | 6.35 | 8.66 | 13.02 | 16.61 |
Total Liabilities | 95.07 | 102.18 | 1,417 | 847.02 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Common Stock | 1,343 | 1,343 | 0.7 | 0.69 |
Additional Paid-In Capital | 1,651 | 1,651 | 15.24 | 11.9 |
Retained Earnings | -2,381 | -2,311 | -1,205 | -764.54 |
Comprehensive Income & Other | 154.36 | 145.79 | -78.97 | -14.56 |
Shareholders' Equity | 767.09 | 827.99 | -1,268 | -766.51 |
Total Liabilities & Equity | 862.17 | 930.17 | 148.63 | 80.51 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Total Debt | 19.56 | 24.94 | 1,381 | 778.35 |
Net Cash (Debt) | 788.5 | 838.43 | -1,293 | -747.82 |
Net Cash Growth | 21.01% | - | - | - |
Net Cash Per Share | 5.91 | 10.63 | -58.42 | -9.36 |
Filing Date Shares Outstanding | 134.28 | 134.28 | 22.41 | 21.86 |
Total Common Shares Outstanding | 134.28 | 134.28 | 22.41 | 21.86 |
Working Capital | 732.7 | 795.68 | -1,292 | -778.97 |
Book Value Per Share | 5.71 | 6.17 | -56.57 | -35.07 |
Tangible Book Value | 752.45 | 812.38 | -1,280 | -780.92 |
Tangible Book Value Per Share | 5.60 | 6.05 | -57.13 | -35.73 |
Machinery | 14.04 | 13.8 | 13.31 | - |
Leasehold Improvements | 5.25 | 5.25 | 5.25 | - |